These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7537949)

  • 1. Granulocyte colony stimulating factor significantly influences neutrophil recovery and duration of hospitalisation in bone marrow transplantation.
    Teoh GK; Tan PH; Goh YT
    Ann Acad Med Singap; 1994 Nov; 23(6):823-7. PubMed ID: 7537949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
    Schmitz N; Dreger P; Zander AR; Ehninger G; Wandt H; Fauser AA; Kolb HJ; Zumsprekel A; Martin A; Hecht T
    Bone Marrow Transplant; 1995 Feb; 15(2):261-6. PubMed ID: 7539668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors.
    Berger C; Bertz H; Schmoor C; Behringer D; Potthoff K; Mertelsmann R; Finke J
    Bone Marrow Transplant; 1999 May; 23(10):983-90. PubMed ID: 10373062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation.
    Uyl-de Groot CA; Richel DJ; Rutten FF
    Eur J Cancer; 1994; 30A(11):1631-5. PubMed ID: 7530471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human granulocyte-colony-stimulating factor in the treatment of patients with neutropenia.
    Boxer LA; Hutchinson R; Emerson S
    Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 2):S39-46. PubMed ID: 1370264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation.
    Linch DC; Scarffe H; Proctor S; Chopra R; Taylor PR; Morgenstern G; Cunningham D; Burnett AK; Cawley JC; Franklin IM
    Bone Marrow Transplant; 1993 Apr; 11(4):307-11. PubMed ID: 7683552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe bactrim-induced neutropenia with reversal of CD4+/CD8+ lymphocyte ratio: response to recombinant human granulocyte-colony stimulating factor (R-metHUG-CSF).
    Krishnan K; Krishnaswamy G
    Clin Lab Haematol; 1998 Jun; 20(3):187-8. PubMed ID: 9681236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia.
    Farese AM; Hunt P; Grab LB; MacVittie TJ
    J Clin Invest; 1996 May; 97(9):2145-51. PubMed ID: 8621805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
    Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
    Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing the target number of nucleated cells and administration of r-metHuG-CSF expedite neutrophil engraftment in allogeneic bone marrow transplantation.
    Kaptan K; Ustün C; Beyan C; Ural AU; Avcu F; Cetin T; Oztürk B; Sengül A; Pekel A; Sertkaya D; Pak Y; Burgess RE; Yalçin A
    Transplant Proc; 2002 Jun; 34(4):1310-4. PubMed ID: 12072348
    [No Abstract]   [Full Text] [Related]  

  • 11. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.
    Kennedy MJ; Davis J; Passos-Coelho J; Noga SJ; Huelskamp AM; Ohly K; Davidson NE
    Cancer Res; 1993 Nov; 53(22):5424-8. PubMed ID: 7693341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial.
    Klumpp TR; Mangan KF; Goldberg SL; Pearlman ES; Macdonald JS
    J Clin Oncol; 1995 Jun; 13(6):1323-7. PubMed ID: 7538555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.
    Frampton JE; Lee CR; Faulds D
    Drugs; 1994 Nov; 48(5):731-60. PubMed ID: 7530630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
    Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.
    Trillet-Lenoir V; Green J; Manegold C; Von Pawel J; Gatzemeier U; Lebeau B; Depierre A; Johnson P; Decoster G; Tomita D
    Eur J Cancer; 1993; 29A(3):319-24. PubMed ID: 7691119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of recombinant human granulocyte-colony stimulating factor in colorectal surgery.
    Wiik HT; Syrjälä HP; Silvennoinen-Kassinen SH; Laurila JJ; Haukipuro KA
    Eur J Clin Microbiol Infect Dis; 1999 Nov; 18(11):819-22. PubMed ID: 10614959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia.
    Locatelli F; Pession A; Zecca M; Bonetti F; Prete L; Carrà AM; Prete A; Montagna D; Comoli P; Taibi RM; Paolucci G
    Bone Marrow Transplant; 1996 Jan; 17(1):31-7. PubMed ID: 8673051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias.
    Bonilla MA; Dale D; Zeidler C; Last L; Reiter A; Ruggeiro M; Davis M; Koci B; Hammond W; Gillio A; Welte K
    Br J Haematol; 1994 Dec; 88(4):723-30. PubMed ID: 7529539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.